^
FLT3-ITD mutation
AML
gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
Nat Commun - 1 week - (New C3)
IDH1 mutation
AML
ivosidenib
Sensitive: A1 - Approval
NCCN - 2 weeks - (New A2)
TP53 mutation
AML
DHODH inhibitor
Sensitive: D – Preclinical
Cancer Res - 2 weeks - (New D)
FLT3 mutation
AML
gilteritinib
Sensitive: A1 - Approval
IDH2 mutation
AML
enasidenib
Sensitive: A1 - Approval
No biomarker
AML
glasdegib
Sensitive: A1 - Approval
No biomarker
AML
azacitidine oral
Sensitive: A1 - Approval
No biomarker
AML
cytarabine / daunorubicin liposomal formulation
Sensitive: A1 - Approval
FLT3 mutation
AML
midostaurin
Sensitive: A1 - Approval
CD33 positive
AML
gemtuzumab ozogamicin
Sensitive: A1 - Approval
No biomarker
AML
venetoclax
Sensitive: A1 - Approval
No biomarker
AML
decitabine
Sensitive: A1 - Approval
Chr t(15;17)
Acute Promyelocytic Leukemia
arsenic trioxide
Sensitive: A1 - Approval
PML-RARA fusion
Acute Promyelocytic Leukemia
arsenic trioxide
Sensitive: A1 - Approval
No biomarker
AML
azacitidine
Sensitive: A1 - Approval
No biomarker
AML
idarubicin hydrochloride
Sensitive: A1 - Approval
IDH2 mutation
AML
venetoclax
Sensitive: A2 - Guideline
IDH1 mutation
AML
venetoclax
Sensitive: A2 - Guideline
FLT3-TKD mutation
AML
midostaurin
Sensitive: A2 - Guideline
FLT3-ITD mutation
AML
midostaurin
Sensitive: A2 - Guideline
FLT3-ITD mutation
AML
gilteritinib
Sensitive: A2 - Guideline
FLT3 mutation
AML
venetoclax
Sensitive: A2 - Guideline
FLT3-ITD mutation
AML
sorafenib
Sensitive: A2 - Guideline
No biomarker
AML
cytarabine
Sensitive: A2 - Guideline
RUNX1-RUNX1T1 fusion
AML
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
CBFB-MYH11 fusion
AML
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
FLT3-TKD mutation
AML
gilteritinib
Sensitive: A2 - Guideline
No biomarker
AML
cytarabine + fludarabine IV + GCSF
Sensitive: A2 - Guideline
No biomarker
AML
cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF
Sensitive: A2 - Guideline
No biomarker
AML
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
No biomarker
Acute Promyelocytic Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
No biomarker
Acute Promyelocytic Leukemia
cytarabine + daunorubicin
Sensitive: A2 - Guideline
FLT3-TKD mutation
AML
cytarabine + midostaurin + daunorubicin
Sensitive: A2 - Guideline
No biomarker
AML
cytarabine + daunorubicin
Sensitive: A2 - Guideline
No biomarker
AML
cytarabine + idarubicin hydrochloride
Sensitive: A2 - Guideline
No biomarker
AML
cytarabine + etoposide IV + mitoxantrone
Sensitive: A2 - Guideline
No biomarker
AML
cytarabine + etoposide IV
Sensitive: A2 - Guideline
No biomarker
AML
cytarabine + cladribine + Nugraf (filgrastim biosimilar)
Sensitive: A2 - Guideline
No biomarker
AML
clofarabine
Sensitive: A2 - Guideline
No biomarker
AML
clofarabine + idarubicin hydrochloride
Sensitive: A2 - Guideline
No biomarker
AML
cytarabine + clofarabine
Sensitive: A2 - Guideline
No biomarker
AML
cytarabine + cladribine + idarubicin hydrochloride + Nugraf (filgrastim biosimilar)
Sensitive: A2 - Guideline
No biomarker
AML
cytarabine + cladribine + mitoxantrone + Nugraf (filgrastim biosimilar)
Sensitive: A2 - Guideline
FLT3 mutation
AML
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
FLT3-ITD mutation + FLT3-TKD mutation
AML
gilteritinib
Sensitive: B - Late Trials
TP53 mutation
AML
APR-246
Sensitive: B - Late Trials
No biomarker
AML
APL-106
Sensitive: B - Late Trials
NPM1 mutation
AML
venetoclax
Sensitive: B - Late Trials
TP53 mutation
AML
venetoclax
Resistant: B - Late Trials
No biomarker
AML
devimistat
Sensitive: B - Late Trials
No biomarker
AML
FLT3 inhibitor
Sensitive: B - Late Trials
FLT3-ITD mutation
AML
cytarabine
Resistant: B - Late Trials
IDH1 mutation
AML
gilteritinib
Resistant: B - Late Trials
WT1 mutation
AML
gilteritinib
Resistant: B - Late Trials
NRAS mutation
AML
gilteritinib
Resistant: B - Late Trials
PTPN11 mutation
AML
gilteritinib
Resistant: B - Late Trials
BRAF mutation
AML
gilteritinib
Resistant: B - Late Trials
CBL mutation
AML
gilteritinib
Resistant: B - Late Trials
KRAS mutation
AML
gilteritinib
Resistant: B - Late Trials
NPM1 mutation
AML
gemtuzumab ozogamicin
Sensitive: B - Late Trials
NPM1 mutation
AML
cytarabine
Sensitive: B - Late Trials
IDH2 mutation
AML
cytarabine
Resistant: B - Late Trials
DNMT3A mutation
AML
azacitidine
Resistant: B - Late Trials
GATA2 mutation
AML
gilteritinib
Resistant: B - Late Trials
IDH2 R172
AML
enasidenib
Sensitive: B - Late Trials
FLT3 mutation
AML
FLT3 inhibitor
Sensitive: B - Late Trials
FLT3‐ITD + WT1 mutation
AML
gilteritinib
Sensitive: B - Late Trials
FLT3‐ITD  + NPM1 mutation
AML
gilteritinib
Sensitive: B - Late Trials
FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation
AML
gilteritinib
Sensitive: B - Late Trials
FLT3‐ITD + DNMT3A mutation
AML
gilteritinib
Sensitive: B - Late Trials
FLT3‐ITD
AML
gilteritinib
Sensitive: B - Late Trials
No biomarker
AML
asparagine cytarabine conjugate
Sensitive: B - Late Trials
No biomarker
AML
GS-4721
Sensitive: B - Late Trials
No biomarker
AML
L-ANN
Sensitive: B - Late Trials
NPM1 mutation
AML
azacitidine
Sensitive: B - Late Trials
NRAS mutation
AML
azacitidine
Resistant: B - Late Trials
EZH2 mutation
AML
azacitidine
Sensitive: B - Late Trials
BCOR mutation
AML
azacitidine
Resistant: B - Late Trials
No biomarker
AML
fludarabine IV + treosulfan
Sensitive: B - Late Trials
NPM1 mutation
AML
SNDX-5613
Sensitive: B - Late Trials
MLL rearrangement
AML
SNDX-5613
Sensitive: B - Late Trials
FLT3-TKD mutation
AML
venetoclax + azacitidine
Sensitive: B - Late Trials
FLT3-ITD mutation
AML
venetoclax + azacitidine
Sensitive: B - Late Trials
FLT3 mutation
AML
venetoclax + azacitidine
Sensitive: B - Late Trials
SRSF2 mutation
AML
lenalidomide
Sensitive: B - Late Trials
No biomarker
AML
CYNK-001
Sensitive: B - Late Trials
FLT3 wild-type
AML
venetoclax
Sensitive: B - Late Trials
No biomarker
AML
IO-202
Sensitive: B - Late Trials
TP53 wild-type
AML
RO5503781
Resistant: B - Late Trials
No biomarker
AML
CFI-400945
Sensitive: B - Late Trials
FLT3 mutation
AML
HM43239
Sensitive: B - Late Trials
No biomarker
AML
KRP-203
Sensitive: B - Late Trials
TNFRSF8 expression
AML
brentuximab vedotin
Sensitive: C1 - Off-label
CBFB-MYH11 fusion
AML
dasatinib
Sensitive: C2 – Inclusion Criteria
RUNX1-RUNX1T1 fusion
AML
dasatinib
Sensitive: C2 – Inclusion Criteria